We further find genetically anchored evidence that aligns with a recent clinical trial60 suggesting human recombinant granulocyte colony-stimulating factor (G-CSF) as a potential treatment option among patients with COVID-19 and severe lymphopenia to mitigate adverse outcomes. This evidence concerns the gene CSF3 and lymphopenia.